Progressive Corp vs Revvity Inc — how do they compare? Progressive Corp trades at $204.09 (market cap $119.71B), while Revvity Inc trades at $110.67 (market cap $12.33B). The key difference: Progressive Corp is far larger — about 9.7× Revvity Inc's market cap, and Progressive Corp pays the higher dividend (6.75%). Which is the better fit depends on your goals.
| PGR | RVTY | |
|---|---|---|
Market Cap | $119.71B | $12.33B |
Sector | Financials | Technology |
52-Week High | $252.68 | $117.75 |
52-Week Low | $190.40 | $82.26 |
Enterprise Value | $127.93B | $14.82B |
Dividend Yield | 6.75% | 0.25% |
Signals from Pluang's Aura AI — not financial advice
Progressive (PGR) trades at $205.9, down 0.99% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with revenue growth from $49.6B in 2022 to $87.6B in 2025 and net income rising to $11.3B. Recent Q2 2026 earnings missed expectations at $4.64 EPS, but premiums and investment income remain solid. Analyst consensus is mixed with a $234.56 price target, indicating potential upside from current levels.
The outlook for PGR is cautiously optimistic given its valuation at a P/E of 10.65 and consistent profitability. Key risks include competitive pressures in auto insurance and market volatility. Investment opportunity lies in its scale and data-driven pricing, though near-term performance may hinge on earnings execution and macroeconomic factors affecting the insurance sector.
RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.
The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.
Trailing returns across standard periods
Latest headlines on both assets
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →